Abstract
Over the past several years, many new adjuvant formulations have been developed to elicit both humoral and cell-mediated responses to antigens. Each of these new formulations must be given in repeated immunizations to yield antibody titers that result in protection. Typically, a minimum of three immunizations is required to invoke antibody titers or cellular responses that are sufficient to neutralize an infection. In addition, the patient may be required to return several years after the last immunization for a final booster immunization to again establish a neutralizing response. These repeated immunizations in developed countries may require repeated visits to the physician and increase the cost of health care. In developing countries and large urban areas, clinics are responsible for immunization of the children against many potentially fatal childhood diseases. Unfortunately, these clinics may have difficulty with repeated immunizations, since the patient population is transient or patients do not understand the necessity for additional shots. Thus, vaccine preparations requiring repeated immunizations are generally inefficient and may not always be successful in preventing disease because of poor patient compliance.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Almeidia, A. J., Alpar, H. O., Williamson, D., and Brown, M. R., 1992, Poly(lactic acid) microspheres as immunological adjuvants for orally delivered cholera toxin B subunit, Biochem. Soc. Trans. 20:316S.
Alonso, M. J., Cohen, S., Park, T. G., Gupta, R. K., Siber, G. R., and Langer, R., 1993, Determinants of release rate of tetanus vaccine from polyester microspheres, Pharm. Res. 10:945–953.
Anderson, K. P., Lucas, C., Hanson, C. V., Londe, H. F., Izu, A., Gregory, T., Ammann, A., Berman, P. W., and Eichberg, J. W., 1989, Effect of dose and immunization schedule on immune response of baboons to recombinant glycoprotein 120 of HIV-1, J. Infect. Dis. 160:960–969.
Barkin, R. M., Samuelson, J. S., Gotlin, L. P., and Barkin, S. Z., 1985, Primary immunization with diphtheria-tetanus toxoids vaccine and diphtheria-tetanus toxoids-pertussis vaccine adsorbed: Comparison of schedules, Pediatr. Infect. Dis. 4:168–171.
Beck, L. R., 1990, Mammal immunization, U.S. Patent 4,919,929.
Birkinshaw, C., Buggy, M., Henn, G. G., and Jones, E., 1992, Irradiation of poly(D,L-lactide), Polym. Degrad. Stab. 38:249–253.
Cabasso, V. J., Louie, R. E., Lo, B., and Dobkin, M. B., 1978, Antibody levels following W138 rabies vaccine, Dev. Biol. Stand. 40:231–235.
Christenson, B., and Bottinger, M., 1991, Changes of the immunological patterns against measles, mumps, and rubella: A vaccination program studied 3 to 7 years after the introduction of a two-dose schedule, Vaccine 9:326–329.
Cleland, J. L., and Langer, R., 1994, Formulation and delivery of proteins and peptides: Design and development strategies, in: Protein Formulations and Delivery (J. L. Cleland and R. Langer, eds.), ACS Books, New York, pp. 1–21.
Cleland, J. L., Powell, M. F., and Shire, S. J., 1993, Development of stable protein formulations: A close look at protein aggregation, deamidation, and oxidation, CRC Crit. Rev. Then Drug Carrier Syst. 10:307–377.
Cleland, J. L., Powell, M. F., Lim, A., Barron, L., Berman, P. W., Eastman, D. J., Nunberg, J. H., Wrin, T., and Vennari, J. C., 1994, Development of a single-shot subunit vaccine for HIV-1, AIDS Res. Hum. Retroviruses 10:s21–s26.
Costantino, W. R., Langer, R., and Klibanov, A., 1994, Moisture-induced aggregation of lyophilized insulin, Pharm. Res. 11:21–29.
Eldridge, J. H., Staas, J. K., Meulbroek, J. A., Tice, T. R., and Gilley, R. M., 1991a, Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies, Infect. Immun. 59:2978–2986.
Eldridge, J. H., Staas, J. K., Meulbroek, J. A., McGhee, J. R., Tice, T. R., and Gilley, R. M., 1991b, Biodegradable microspheres as a vaccine delivery, Mol. Immunol. 28:287–294.
Eppstein, D. A., and Schryver, B. B., 1990, Controlled release of macromolecular Polypeptides, U.S. Patent 4,962,091.
Folkman, M. J., and Langer, R. S., 1983, Systems for the controlled release of macromolecules, U.S. Patent 4,391,797.
Furr, B. J. A., and Hutchinson, F. G., 1992, A biodegradable delivery system for peptides: Preclinical experience with the gonadotropin-release hormone agonist Zoladex®, J. Control. Rel. 21:117–128.
Grandfils, C., Flandroy, P., Nuhant, N., Barbette, S., Jérome, R., Teyssié, P., and Thibaut, A., 1992, Preparation of poly (d,l) lactide microspheres by emulsion-solvent evaporation, and their clinical applications as a convenient embolic material, J. Biomed. Mater. Res. 26:467–479.
Hageman, M. J., Bauer, J. M., Possert, P. L., and Darrington, R. T., 1992, Preformulation studies oriented toward sustained delivery of recombinant somatotropins, J. Agric. Food Chem. 40:348–355.
Haigwood, N. L., Nara, P. L., Brooks, E., Van Nest, G. A., Ott, G., Higgins, K. W., Dunlop, N., Scandella, C. J., Eichberg, J. W., and Steimer, K. S., 1992, Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons, J. Virol. 66:172–182.
Hardy, G. E., Hopkins, C. C., Linnemann, C. C., Hatch, M. H., Chambers, J. C., and Witte, J. J., 1970, Trivalent oral poliovirus vaccine: A comparison of two infant immunization schedules, Pediatrics 45:444–448.
Hartas, S. R., Collett, J. H., and Booth, C., 1992, The influence of gamma-irradiation on the release of melatonin from poly(lactide-coglycolide) microspheres, Proc. Int. Symp. Control. Rel. Bioact. Mater. 19:321–322.
Haskill, J. S., and Hunt, J. W., 1967a, Radiation damage to crystalline ribonuclease: Identification of Polypeptide chain breakage in the denatured and aggregated products, Radiat. Res. 32:827–848.
Haskill, J. S., and Hunt, J. W., 1967b, Radiation damage to crystalline ribonuclease: Importance of free radicals in the formation of denatured and aggregated products, Radiat. Res. 32:606–624.
Hazrati, A. M., Lewis, D. H., Atkins, T. J., Stohrer, R. C., McPhillips, C. A., and Little, J. E., 1993, Salmonella enteritidis vaccine utilizing biodegradable microspheres, Proc. Int. Symp. Control. Rel. Bioact. Mater. 20:101–102.
Heller, J., 1993, Polymers for controlled parenteral delivery of peptides and proteins, Adv. Drug Deliv. Rev. 10:163–204.
Hess, G., Hingst, V., Cseke, J., Bock, H. L., and Clemens, R., 1992, Influence of vaccination schedules and host factors on antibody response following hepatitis B vaccination, Eur. J. Clin. Microbiol. Infect. Dis. 11:334–340.
Horacek, I., and Kudlacek, L., 1993, Influence of molecular weight on the resistance of polylactide fibers by radiation sterilization, J. Appl. Polym. Sci. 50:1–5.
Hutchinson, F. G., 1988, Continuous release pharmaceutical compositions, U.S. Patent 4,767,628.
Jepson, M. A., Simmons, N. L., O’Hagen, D. T., and Hirst, B. H., 1994, Comparison of poly(DL-lactide-coglycolide) and polystyrene microsphere targeting to intestinal M cells, J. Drug Target. 1:245–249.
Jertborn, M., Svennerholm, A.-M., and Holmgren, J., 1993, Evaluation of different immunization schedules for oral cholera B subunit-whole cell vaccine in Swedish volunteers, Vaccine 11:1007–1012.
Jones, A. J. S., Nguyen, T. H., Cleland, J. L., and Pearlman, R., 1994, New delivery systems for recombinant proteins — practical issues from proof of concept to clinic, in: Trends and Future Perspectives in Peptide and Protein Drug Delivery (V. H. L. Lee, M. Hashida, and Y. Mizushima, eds.), Harwood Academic, Amsterdam (in press).
Just, M., Kanra, G., Bogaerts, H., Berger, R., Ceyhan, M., and Petre, J., 1991, Two trials of an acellular DTP vaccine in comparison with a whole-cell DTP vaccine in infants: Evaluation of two PT doses and two vaccination schedules, Dev. Biol. Stand. 73:275–283.
Just, M., Berger, R., Drechsler, H., Brantschen, S., and Glück, R., 1992, A single vaccination with an inactivated hepatitis A liposome vaccine induces protective antibodies after only two weeks, Vaccine 10:737–739.
Kalpana, K. R., and Park, K., 1993, Biodegradable hydrogels in drug delivery, Adv. Drug Deliv. Rev. 11:59–84.
Kessler, D. A., 1992, The basis of the FDA’s decision on breast implants, N. Engl. J. Med. 326:1713–1715.
Khan, M. Z. I., Opdebeeck, J. P., and Tucker, I. G., 1994, Immunopotentiation and delivery systems for antigens for single-step immunization: Recent trends and progress, Pharm. Res. 11:2–11.
Langer, R., 1993, Polymer-controlled drug delivery systems, Acc. Chem. Res. 26:537–542.
Lewis, D. H., 1990, Controlled release of bioactive agents from lactide glycolide polymers, in: Drugs and the Pharmaceutical Sciences (M. Chasin and R. Langer, eds.), Vol. 45, Dekker, New York, pp. 1–42.
Ludwig, N. H., and Bosvenue, R. J., 1982, Controlled release parasitic formulations and method, U.S. Patent 4,331,652.
Ludwig, N. H., and Ose, E. E., 1981, Controlled release formulations and method of treatment, U.S. Patent 4,293,539.
Marx, P. A., Compans, R. W., Gettie, A., Staas, J. K., Gilley, R. M., Mulligan, M. J., Yamshchikov, G. V., Chen, D., and Eldridge, J. H., 1993, Protection against vaginal SIV transmission with microencapsulated vaccine, Science 260:1323–1327.
Miller, R. A., Brady, J. M., and Cutright, D. E., 1977, Degradation rates of oral resorbable implants (polylactates and polyglycolates): Rate modification with changes in PLA/PGA copolymer ratios, J. Biomed. Mater. Res. 11:711–719.
Ogawa, Y., Yamamoto, M., Okada, H., Yashiki, T., and Shimamoto, T., 1988a, Anew technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly(lactic/glycolic) acid, Chem. Pharm. Bull. 36:1095–1103.
Ogawa, Y., Yamamoto, M., Okada, H., Yashiki, T., and Shimamoto, T., 1988b, Controlled-release of leuprolide acetate from polylactic acid or copoly(lactic/glycolic) acid microcapsules: Influence of molecular weight and copolymer ratio of polymer, Chem. Pharm. Bull. 36:1502–1507.
Ogawa, Y., Yamamoto, M., Okada, H., Yashiki, T., and Shimamoto, T., 1988c, In vivo release profiles of leuprolide acetate from microcapsules prepared with polylactic acids or copoly(lactic/glycolic) acids and in vivo degradation of these polymers, Chem. Pharm. Bull. 36:2576–2581.
O’Hagen, D. T., Jeffery, H., and Davis, S. S., 1993, Poly(lactide-co-glycolide) microparticles as controlled release vaccines, Proc. Int. Symp. Control. Rel. Bioact. Mater. 20:59–60.
Okada, H., Ogawa, Y., and Yashiki, T., 1987, Prolonged release microcapsule and its production, U.S. Patent 4,652,441.
Okada, H., Inoue, Y., Heya, T., Ueno, H., Ogawa, Y., and Toguchi, H., 1991, Pharmacokinetics of once-a-month injectable microspheres of leuprolide acetate, Pharm. Res. 8:787–791.
Pierce, N. F., 1984, Induction of optimal mucosal antibody responses: Effects of age, immunization route(s), and dosing schedule in rats, Infect. Immun. 43:341–346.
Preis, I., and Langer, R. S., 1979, A single-step immunization by sustained antigen release, J. Immunol. Methods 28:193–197.
Reid, R. H., Boedeker, E. C., McQueen, C. E., Davis, D., Tseng, L. Y, Kodak, J., and Sau, K., 1993, Preclinical evaluation of microencapsulated CFA/II oral vaccine against enterotoxigenic E. coli, Vaccine 11:159–167.
Serufo, J. C., Lima, M. G., Ribeiro, M. F. B., and Santos, J. L. D., 1987, Comparative study of schemes of preexposure vaccination against human rabies: Importance of the interval between doses and laboratory control, Cienc. Cult. (Sao Paulo) 39:193–197.
Singh, M., Singh, O., Singh, A., and Talwar, G. P., 1992, Immunogenicity studies on diphtheria toxoid loaded biodegradable microspheres, Int. J. Pharm. 85:R5–R8.
Spenlehauer, G., Vert, M., Benoit, J. P., and Boddaert, A., 1989, In vitro and in vivo degradation of poly (D,L-lactide/glycolide) type microspheres made by solvent evaporation method, Biomaterials 10:557–563.
Tice, T. R., Gilley, R. M., Eldridge, J. H., Staas, J. K., Hollingshead, M. G., and Shannon, W. M., 1991, Method of potentiating an immune response, U.S. Patent 5,075,109.
Visscher, G. E., Robinson, R. L., Maulding, H. V., Fong, J. W., Pearson, J. E., and Argentieri, G. J., 1985, Biodegradation of and tissue reaction to 50:50 poly(DL-lactide-co-glycolide) microcapsules, J. Biomed. Mater. Res. 19:349–365.
Visscher, G. E., Robinson, R. L., and Argentieri, G. J., 1987, Tissue response to biodegradable injectable microcapsules, J. Biomater. Appl. 2:118–131.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media New York
About this chapter
Cite this chapter
Cleland, J.L. (1995). Design and Production of Single-Immunization Vaccines Using Polylactide Polyglycolide Microsphere Systems. In: Powell, M.F., Newman, M.J. (eds) Vaccine Design. Pharmaceutical Biotechnology, vol 6. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1823-5_18
Download citation
DOI: https://doi.org/10.1007/978-1-4615-1823-5_18
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5737-7
Online ISBN: 978-1-4615-1823-5
eBook Packages: Springer Book Archive